單核苷酸多態性與乳腺癌化療應答_《中國普外基礎與臨床雜志》

作者：

唐金海 ¹ , 趙建華 ²

1.江蘇省腫瘤醫院普外科（南京210009）;;
2.江蘇省腫瘤醫院、江蘇省臨床檢驗中心分子室（南京210009）;

關鍵詞：

多態性化療個體化治療乳腺癌

視頻：

導出 下載 收藏 掃碼 引用

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

目的探討單核苷酸多態性（SNP）與乳腺癌常規化療藥物治療應答間的相關性及其在指導個體化治療中的價值。方法檢索Pub-Medline和中國CHKD期刊數據庫，對近年來此領域有代表性的文獻進行整理、歸納。結果多種藥物代謝相關基因存在SNP現象，且與藥物效應個體多樣性有著密切聯系。人種、地域、環境、基因間或藥物間相互作用可能會對這種關系產生影響。結論 SNP研究對于優化個體用藥具有重要的應用前景，但多基因多SNP組合分析以及大樣本、前瞻性隨機對照研究還非常必要。

引用本文： 唐金海,趙建華. 單核苷酸多態性與乳腺癌化療應答. 中國普外基礎與臨床雜志, 2008, 15(12): 950-953. doi: 復制

1.	International HapMap Consortium. A haplotype map of the human genome [J]. Nature, 2005; 437(7063)∶ 1299.
2.	Giacomini KM, Brett CM, Altman RB, et al. The pharmacogenetics research network: from SNP discovery to clinical drug response [J]. Clin Pharmacol Ther， 2007; 81(3)∶ 328.
3.	Choi JY, Nowell SA, Blanco JG, et al. The role of genetic variability in drug metabolism pathways in breast cancer prognosis [J]. Pharmacogenomics, 2006; 7(4)∶ 613.
4.	Kim SJ, Noguchi S. Prediction of response to docetaxel in breast cancer [J]. Gan To Kagaku Ryoho, 2008; 35(2)∶ 190.
5.	Marsh S, Somlo G, Li X, et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer [J]. Pharmacogenomics J， 2007; 7(5)∶362.
6.	Nakajima M, Fujiki Y, Kyo S, et al. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1 [J]. J Clin Pharmacol, 2005; 45(6)∶ 674.
7.	范偉，楊金巧，伍曉汀. 乳腺浸潤性導管癌中PS2和GSTπ的表達及臨床意義 [J]. 中國普外基礎與臨床雜志， 2004; 11(1)∶14.
8.	Medeiros R, Pereira D, Afonso N, et al. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome [J]. Int J Clin Oncol, 2003; 8(3)∶ 156.
9.	Sweeney C, McClure GY, Fares MY, et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism [J]. Cancer Res, 2000; 60(20)∶5621.
10.	Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo [J]. Proc Natl Acad Sci USA, 2000; 97(7)∶ 3473.
11.	Bosch TM, Huitema AD, Doodeman VD, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel [J]. Clin Cancer Res, 2006; 12(19)∶ 5786.
12.	沈紹華，葉欣，顧龍君. 微管蛋白與多藥耐藥 [J]. 國際腫瘤學雜志， 2006; 33(2)∶104.
13.	Wiesen KW, Xia S, Yang CP, et al. Wild-type class Ⅰ beta-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a beta-tubulin mutation [J]. Cancer Lett， 2007; 257(2)∶ 227.
14.	Hari M, Loganzo F, Annable T, et al. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules [J]. Mol Cancer Ther， 2006; 5(2)∶270.
15.	Maeno K, Ito K, Hama Y, et al. Mutation of the class Ⅰ beta-tubulin gene does not predict response to paclitaxel for breast cancer [J]. Cancer Lett， 2003; 198(1)∶ 89.
16.	Christine BA, Jiyoung A, Keshav KS, et al. Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer[J]. Cancer Res, 2005; 65(3)∶1105.
17.	Ambrosone CB, Sweeney C, Coles BF, et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer [J]. Cancer Res， 2001; 61(19)∶ 7130.
18.	Kafka A, Sauer G, Jaeger C, et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer [J]. Int J Oncol, 2003; 22(5)∶ 1117.
19.	Honjo Y, Hrycyna CA, Yan QW, et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells [J]. Cancer Res, 2001; 61(18)∶ 6635.
20.	Concin N, Hofstetter G, Berger A, et al. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo [J]. Clin Cancer Res, 2005; 11(23)∶ 8372.
21.	Xu Y, Yao L, Ouyang T, et al. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer [J]. Clin Cancer Res, 2005; 11(20)∶ 7328.
22.	Sullivan A， Syed N, Gasco M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo [J]. Oncogene, 2004; 23(19)∶ 3328.
23.	Xie HJ, Yasar U, Lundgren S, et al. Role of Polymorphic human CYP2B6 in cyclophosphamide bioactivation [J]. Pharmacogenomics J, 2003; 3 (1)∶ 53.
24.	Petros WP, Hopkins PJ, Spruill S, et al. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer [J]. J Clin Oncol, 2005; 23(25)∶ 6117.
25.	Sweeney C, Ambrosone CB, Joseph L, et al. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment [J]. Int J Cancer, 2003; 103(6)∶810.
26.	Cai S, Ernstberger A, Wang H, et al. In vivo selection of hematopoietic stem cells transduced at a low multiplicity-of-infection with a foamy viral MGMT(P140K) vector [J]. Exp Hematol, 2008; 36(3)∶ 283.
27.	Pusztai L, Symmans FW, Hortobagyi GN. Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer [J]. Breast Cancer, 2005; 12(2)∶ 73.
28.	Bewick MA, Conlon MS, Lafrenie RM. Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer [J]. Breast Cancer Res Treat, 2008; 11(1)∶ 93.
29.	Abecasis G, Tam PK, Bustamante CD, et al. Human Genome Variation 2006: emerging views on structural variation and large-scale SNP analysis [J]. Nat Genet, 2007; 39(2)∶153.

1. International HapMap Consortium. A haplotype map of the human genome [J]. Nature, 2005; 437(7063)∶ 1299.
2. Giacomini KM, Brett CM, Altman RB, et al. The pharmacogenetics research network: from SNP discovery to clinical drug response [J]. Clin Pharmacol Ther， 2007; 81(3)∶ 328.
3. Choi JY, Nowell SA, Blanco JG, et al. The role of genetic variability in drug metabolism pathways in breast cancer prognosis [J]. Pharmacogenomics, 2006; 7(4)∶ 613.
4. Kim SJ, Noguchi S. Prediction of response to docetaxel in breast cancer [J]. Gan To Kagaku Ryoho, 2008; 35(2)∶ 190.
5. Marsh S, Somlo G, Li X, et al. Pharmacogenetic analysis of paclitaxel transport and metabolism genes in breast cancer [J]. Pharmacogenomics J， 2007; 7(5)∶362.
6. Nakajima M, Fujiki Y, Kyo S, et al. Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1 [J]. J Clin Pharmacol, 2005; 45(6)∶ 674.
7. 范偉，楊金巧，伍曉汀. 乳腺浸潤性導管癌中PS2和GSTπ的表達及臨床意義 [J]. 中國普外基礎與臨床雜志， 2004; 11(1)∶14.
8. Medeiros R, Pereira D, Afonso N, et al. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome [J]. Int J Clin Oncol, 2003; 8(3)∶ 156.
9. Sweeney C, McClure GY, Fares MY, et al. Association between survival after treatment for breast cancer and glutathione S-transferase P1 Ile105Val polymorphism [J]. Cancer Res, 2000; 60(20)∶5621.
10. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo [J]. Proc Natl Acad Sci USA, 2000; 97(7)∶ 3473.
11. Bosch TM, Huitema AD, Doodeman VD, et al. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel [J]. Clin Cancer Res, 2006; 12(19)∶ 5786.
12. 沈紹華，葉欣，顧龍君. 微管蛋白與多藥耐藥 [J]. 國際腫瘤學雜志， 2006; 33(2)∶104.
13. Wiesen KW, Xia S, Yang CP, et al. Wild-type class Ⅰ beta-tubulin sensitizes Taxol-resistant breast adenocarcinoma cells harboring a beta-tubulin mutation [J]. Cancer Lett， 2007; 257(2)∶ 227.
14. Hari M, Loganzo F, Annable T, et al. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of β-tubulin (Asp26Glu) and less stable microtubules [J]. Mol Cancer Ther， 2006; 5(2)∶270.
15. Maeno K, Ito K, Hama Y, et al. Mutation of the class Ⅰ beta-tubulin gene does not predict response to paclitaxel for breast cancer [J]. Cancer Lett， 2003; 198(1)∶ 89.
16. Christine BA, Jiyoung A, Keshav KS, et al. Polymorphisms in genes related to oxidative stress (MPO, MnSOD, CAT) and survival after treatment for breast cancer[J]. Cancer Res, 2005; 65(3)∶1105.
17. Ambrosone CB, Sweeney C, Coles BF, et al. Polymorphisms in glutathione S-transferases (GSTM1 and GSTT1) and survival after treatment for breast cancer [J]. Cancer Res， 2001; 61(19)∶ 7130.
18. Kafka A, Sauer G, Jaeger C, et al. Polymorphism C3435T of the MDR-1 gene predicts response to preoperative chemotherapy in locally advanced breast cancer [J]. Int J Oncol, 2003; 22(5)∶ 1117.
19. Honjo Y, Hrycyna CA, Yan QW, et al. Acquired mutations in the MXR/BCRP/ABCP gene alter substrate specificity in MXR/BCRP/ABCP-overexpressing cells [J]. Cancer Res, 2001; 61(18)∶ 6635.
20. Concin N, Hofstetter G, Berger A, et al. Clinical relevance of dominant-negative p73 isoforms for responsiveness to chemotherapy and survival in ovarian cancer: evidence for a crucial p53-p73 cross-talk in vivo [J]. Clin Cancer Res, 2005; 11(23)∶ 8372.
21. Xu Y, Yao L, Ouyang T, et al. p53 Codon 72 polymorphism predicts the pathologic response to neoadjuvant chemotherapy in patients with breast cancer [J]. Clin Cancer Res, 2005; 11(20)∶ 7328.
22. Sullivan A， Syed N, Gasco M, et al. Polymorphism in wild-type p53 modulates response to chemotherapy in vitro and in vivo [J]. Oncogene, 2004; 23(19)∶ 3328.
23. Xie HJ, Yasar U, Lundgren S, et al. Role of Polymorphic human CYP2B6 in cyclophosphamide bioactivation [J]. Pharmacogenomics J, 2003; 3 (1)∶ 53.
24. Petros WP, Hopkins PJ, Spruill S, et al. Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer [J]. J Clin Oncol, 2005; 23(25)∶ 6117.
25. Sweeney C, Ambrosone CB, Joseph L, et al. Association between a glutathione S-transferase A1 promoter polymorphism and survival after breast cancer treatment [J]. Int J Cancer, 2003; 103(6)∶810.
26. Cai S, Ernstberger A, Wang H, et al. In vivo selection of hematopoietic stem cells transduced at a low multiplicity-of-infection with a foamy viral MGMT(P140K) vector [J]. Exp Hematol, 2008; 36(3)∶ 283.
27. Pusztai L, Symmans FW, Hortobagyi GN. Development of pharmacogenomic markers to select preoperative chemotherapy for breast cancer [J]. Breast Cancer, 2005; 12(2)∶ 73.
28. Bewick MA, Conlon MS, Lafrenie RM. Polymorphisms in manganese superoxide dismutase, myeloperoxidase and glutathione-S-transferase and survival after treatment for metastatic breast cancer [J]. Breast Cancer Res Treat, 2008; 11(1)∶ 93.
29. Abecasis G, Tam PK, Bustamante CD, et al. Human Genome Variation 2006: emerging views on structural variation and large-scale SNP analysis [J]. Nat Genet, 2007; 39(2)∶153.

《中國普外基礎與臨床雜志》

單核苷酸多態性與乳腺癌化療應答

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

《中國普外基礎與臨床雜志》

單核苷酸多態性與乳腺癌化療應答

摘要 全文 圖表 視頻 參考文獻 施引文獻 補充材料

Format

Content

摘要全文圖表視頻參考文獻施引文獻補充材料